Appetite signalling
It mimics GLP-1 activity, helping people feel fuller and reducing appetite when prescribed alongside diet and lifestyle support.
Newly authorised in the UK
Foundayo skinny pill UK
Foundayo, also called orforglipron and sometimes described as the skinny pill, is a once-daily GLP-1 tablet authorised by the MHRA on 10 August 2026 for weight management and type 2 diabetes. It is not listed in our UK provider tables yet, so this page explains what is known now and lets you join the alert list for availability and pricing.
What is it?
Foundayo is the new GLP-1 skinny pill people are searching for
Orforglipron works on the GLP-1 pathway, the same broad appetite-signalling route associated with Wegovy and other modern weight-loss medicines. The difference people will notice first is practical: Foundayo is a daily weight-loss tablet rather than an injection.
No injection routine
Foundayo is taken once daily as a tablet, and available medicine information says it can be taken with or without food.
No UK listing price yet
The medicine is authorised, but UK private provider pricing and the first live pharmacy listings are still the missing pieces.
How it compares
Foundayo vs Mounjaro vs Wegovy
These medicines are not interchangeable, and the right route depends on clinical suitability. This snapshot focuses on format, routine and availability rather than pretending Foundayo has live UK price data before providers publish it.
| Medicine | Form | Routine | Published result | UK price |
|---|---|---|---|---|
| New tabletFoundayoOrforglipron | Daily tablet | No food or water restrictions | 11.2% in ATTAIN-1 | Not listed yet |
| InjectionMounjaroTirzepatide | Weekly injection | No meal timing rule | Higher trial averages | Compare live listings |
| InjectionWegovySemaglutide injection | Weekly injection | No meal timing rule | Around 15% in major trials | Compare live listings |
| TabletWegovy pillOral semaglutide | Daily tablet | Empty-stomach routine | 13.6% in trial data | Compare oral listings |
Starts low and steps up
Available dose information lists 0.8mg as the starting dose, then step-ups through 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg where clinically suitable. A prescriber can adjust based on response and tolerability.
Mostly digestive in trials
The most common side effects reported for GLP-1 medicines are usually nausea, constipation, diarrhoea and vomiting. Dose increases are one of the moments where people tend to notice them most.
Prescription-only medicine
Foundayo is not an over-the-counter slimming product. A registered prescriber should check eligibility, other medicines, health history and ongoing monitoring needs.
Authorisation is not funding
MHRA authorisation is an important regulatory step, but routine NHS weight-management access depends on separate NICE and NHS decisions.
Price alert
Get Foundayo pricing updates first
We will add comparison tables when real UK provider listings exist. Until then, join the waitlist and we will send a short update when Foundayo becomes available through a UK provider.
Questions
Foundayo skinny pill questions, answered carefully
Can I get Foundayo on the NHS?
Not yet for routine weight-management access. MHRA authorisation covers safety, quality and efficacy, but NHS funding and rollout depend on separate NICE and NHS decisions.
When will Foundayo be available privately in the UK?
Eli Lilly has not confirmed a UK private launch date. Private providers may list it after supply and pharmacy routes are ready, but any exact date is still unconfirmed.
How much will Foundayo cost in the UK?
No UK private price has been announced. Any specific UK monthly price should be treated as an estimate until a registered UK provider lists it.
How is Foundayo different from the Wegovy pill?
Both are daily GLP-1 tablets, but Foundayo is designed to be taken with or without food and without water restrictions. Oral Wegovy has stricter timing rules around food, drink and other medicines.
What are the common side effects?
Trial data and medicine information for GLP-1 treatments point mainly to digestive side effects such as nausea, constipation, diarrhoea and vomiting, especially around dose increases.
Is Foundayo the new skinny pill?
Foundayo is being searched for as the skinny pill because it is a weight-loss tablet rather than an injection. It is still a prescription-only medicine for people who meet clinical criteria, not an over-the-counter slimming aid.
Sources checked: GOV.UK MHRA authorisation notice, Eli Lilly Foundayo medicine information, and published orforglipron trial reporting. This page is general information only and is not medical advice.